期刊文献+

血清PSA及PSA密度与前列腺癌分级分期的关系 被引量:4

Correlations of Serum PSA and PSA Density with Grading and Staging of Prostatic Cancer
原文传递
导出
摘要 目的:提高前列腺癌(PCa)的诊断水平。方法:回顾了60例经穿刺活检确诊PCa患者的临床资料。结果:60例PCa患者中,血清T-PSA含量、F-PSA含量、F/T分别与PCa Gleason分级、临床分期均呈正相关,F/T与PCa Gleason分级、临床分期均无显著相关。结论:PCa患者的血清T-PSA、F-PSA和PSAD与Gleason分级和临床分期存在相关,提示可能通过检测血清T-PSA、F-PSA和PSAD预测PCa恶性程度及预后,有利于PCa的筛查及制定合理的治疗方案。 Objective: To improve diagnosis level of prostatic cancer. Methods: the clinical data of 60 cases of prostate cancer patients was retrospective analyzed who were diagnosed by needle biopsy was carried out. Results: in 60 cases of prostatic cancer patients,serum T-PSA content,F-PSA content and F/T were respectively positively correlated with and Gleason grading and clinical staging of prostatic cancer, while F/T had no significant correla- tion with Gleason grading and clinical staging of prostatic cancer. Conclusions:Serum T-PSA,F-PSA and PSAD of patients with prostatic cancer were respectively associated with clinical staging, indicating that it was possible to predict the grading malignancy and prognosis of prostatic cancer by detecting serum T-PSA,F-PSA and PSAD. It helped to screen prostatic cancer and prepare reasonable treatment plan.
机构地区 解放军第 解放军第
出处 《临床泌尿外科杂志》 北大核心 2011年第8期597-599,共3页 Journal of Clinical Urology
关键词 前列腺癌 前列腺特异性抗原 诊断 病理分级 临床分期 prostatic cancer prostatic specific antigen diagnose pathological grading clinical staging
  • 相关文献

参考文献10

  • 1Demura T,Shinohara N,Tanaka M,et al. The propor tion of free to total prostate specific antigen: a meth od of detecting prostate carcinoma[J].Cancer, 1996 77(6): 1137-1143.
  • 2Aihara M,Lebovitz R M,Wheeler T M,et al. Prostate specific antigen and gleason grade= an immunohisto- chemical study of prostate cancer[J]. J Urol, 1994, 151(6): 1558-1564.
  • 3Christensson A; BjOrk T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-an- tichymotrypsin as an indicator of prostate caneer[J]. J Uro1,1993,150(1) : 100-105.
  • 4周利群,陈为民,那彦群,黄有媛,冯陶,郝金瑞,潘柏年,薛兆英,顾方六,郭应禄.良性前列腺增生与前列腺癌患者血清总PSA水平与游离PSA比值的比较[J].中华泌尿外科杂志,2002,23(6):354-357. 被引量:74
  • 5Milkovic B, Hadzi-Djokic J, Dzamic Z, et al. The sig- nificance of TPSA, free to total PSA ratio and PSA density in prostate carcinoma diagnostics [J].Acta Chir Iugosl,2007,54(4) : 105-107.
  • 6Figler B D, Reuther A M, Dhar N, et al. Preoperative PSA is still predictive of cancer volume and grade in late PSA era[J]. Urology,2007,70(4):711-716.
  • 7Lerner S E,Jacobsen S J, Lilja H, et al. Free, com- plexed,and total serum prostate-speci{ic antigen con- centrations and their proportions in predicting stage, grade, and deoxyribonucleic acid plo!dy in patients with adenocarcinoma of the prostate [J]. Urology, ]996,48(2) : 240-248.
  • 8Pepe P, Panella P, Pietropaolo F, et al. Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSA <or10 ng/ml[J].? Urol Int, 2006,76(3): 232- 235.
  • 9Saidi S, Georgiev V, Stavridis S, et al. Does prostate specific antigen density correlates with aggressiveness of the prostate cancer[J].? Hippokratia, 2Q09,13 (4) : 232-236.
  • 10Radwan M H, Yah Y, LulyJ R, etal. Prostate-spe- cific antigen density predicts adverse pathology and increased risk of biochemical failure [J]. Urology, 2007, 69(6): 1121-1127.

二级参考文献1

共引文献73

同被引文献69

  • 1吴琪俊,徐剑锋,施榕.前列腺癌易感基因及遗传流行病学研究进展[J].上海交通大学学报(医学版),2011,31(5):672-675. 被引量:10
  • 2Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigendensity:a means of distinguishing benign prostatic hypertrophy andprostate cancer[J]. Urology,1992,147:815-816.
  • 3Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram topredict pathologic stage of prostate cancer given prostate-specificantigen level, clinical stage, and biopsy Gleason score (Partin tables)based on cases from 2000 to 2005[J]. Urology,2007,69:1095-1101.
  • 4Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progressionfollowing radical prostatectomy. A multivariate analysis of 721 menwith long-term follow-up [J]. Am J Surg Pathol, 1996,20:286-292.
  • 5Moussa AS, Li J, Soriano M, et al. Prostate biopsy clinical andpathological variables that predict significant grading changes inpatients with intermediate and high grade prostate cancer[J]. BJU Int,2009,103:43-48.
  • 6Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis andstaging of prostate cancer[J]. Curr Opin Urol,2009,19:232-237.
  • 7Miyake H, Kurahashi T, Takenaka A, et al. Improved accuracy forpredicting the Gleason score of prostate cancer by increasing thenumber of transrectal biopsy cores[J]. Urol Int,2007,9:302-306.
  • 8Hong SK, Han BK, Lee ST, et al. Prediction of Gleason scoreupgrading in low-risk prostate cancers diagnosed via mult (> or = 12)-core prostate biopsy[J]. World J Urol,2009,27:271-276.
  • 9Magheli A, Hinz S, Hege C, et al. Prostate specific antigen density topredict prostate cancer upgrading in a contemporary radicalprostatectomy series:a single center experience [J]. J Urol,2010,183:126-131.
  • 10Tseng KS, Landis P, Epstein JI, et al. Risk stratification of menchoosing surveillance for low risk prostate Cancer [J]. J Urol,2010,183:1779-1785.

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部